Advertisement

Journal of Gastroenterology

, Volume 51, Issue 1, pp 30–34 | Cite as

NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers

  • Yoko Oshima
  • Hideaki ShimadaEmail author
  • Satoshi Yajima
  • Tatsuki Nanami
  • Kazuyuki Matsushita
  • Fumio Nomura
  • Osamu Kainuma
  • Nobuhiro Takiguchi
  • Hiroaki Soda
  • Takeshi Ueda
  • Toshihiko Iizasa
  • Naoto Yamamoto
  • Hiroshi Yamamoto
  • Matsuo Nagata
  • Sana Yokoi
  • Masatoshi Tagawa
  • Seiko Ohtsuka
  • Akiko Kuwajima
  • Akihiro Murakami
  • Hironori Kaneko
Original Article—Alimentary Tract

Abstract

Background

Although serum NY-ESO-1 antibodies (s-NY-ESO-1-Abs) have been reported in patients with esophageal carcinoma, this assay system has not been used to study a large series of patients with various other cancers.

Patients and methods

Serum samples of 1969 cancer patients [esophageal cancer (n = 172), lung cancer (n = 269), hepatocellular carcinoma (n = 91), prostate cancer (n = 358), gastric cancer (n = 313), colorectal cancer (n = 262), breast cancer (n = 365)] and 74 healthy individuals were analyzed using an originally developed enzyme-linked immunosorbent assay system for s-NY-ESO-1-Abs. The optical density cut-off value, determined as the mean plus three standard deviations for serum samples from the healthy controls, was fixed at 0.165. Conventional tumor markers were also evaluated in patients with esophageal carcinoma.

Results

The positive rate of s-NY-ESO-1-Abs in patients with esophageal cancer (31 %) was significantly higher than that in the other groups: patients with lung cancer (13 %), patients with hepatocellular carcinoma (11 %), patients with prostate cancer (10 %), patients with gastric cancer (10 %), patients with colorectal cancer (8 %), patients with breast cancer (7 %), and healthy controls (0 %). The positive rate of s-NY-ESO-1-Abs was comparable to that of serum p53 antibodies (33 %), squamous cell carcinoma antigen (36 %), carcinoembryonic antigen (26 %), and CYFRA 21-1 (18 %) and gradually increased with the tumor stage.

Conclusions

The positive rate of s-NY-ESO-1-Abs was significantly higher in patients with esophageal cancer than in patients with the other types of cancers. On the basis of its high specificity and sensitivity, even in patients with stage I tumors, s-NY-ESO-1-Abs may be one of the first choices for esophageal cancer.

Keywords

NY-ESO-1 Serum autoantibody Tumor marker Esophageal cancer Enzyme-linked immunosorbent assay 

Abbreviations

CEA

Carcinoembryonic antigen

PBS

Phosphate-buffered saline

SCC

Squamous cell carcinoma

SCC-Ag

Squamous cell carcinoma antigen

s-NY-ESO-1-Abs

Serum NY-ESO-1 antibodies

Notes

Acknowledgments

We thank the Ministry of Education, Culture, Sports, Science and Technology of Japan for Grants-in-Aid for Scientific Research (nos. 24591961 and 21591717).

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Shimada H, Yajima Satoshi, Oshima Yoko, et al. Impact of serum biomarkers on esophageal squamous cell carcinoma. Esophagus. 2012;9:131–40.CrossRefGoogle Scholar
  2. 2.
    Shimada H, Nabeya Y, Okazumi S, et al. Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery. 2003;133:486–94.PubMedCrossRefGoogle Scholar
  3. 3.
    Shimada H, Nabeya Y, Okazumi S, et al. Prognostic significance of CYFRA 21-1 in patients with esophageal squamous cell carcinoma. J Am Coll Surg. 2003;196:573–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Lubin R, Zalcman G, Bouchet L, et al. Serum p53 antibodies as early markers of lung cancer. Nat Med. 1995;1:701–2.PubMedCrossRefGoogle Scholar
  5. 5.
    Shimada H, Kagaya A, Shiratori T, et al. Detection of anti-CUEC-23 antibodies in serum of patients with esophageal squamous cell carcinoma: a possible new serum marker for esophageal cancer. J Gastroenterol. 2009;44:691–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Shimada H, Takeda A, Arima M, et al. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer. 2000;89:1677–83.PubMedCrossRefGoogle Scholar
  7. 7.
    Shimada H, Nabeya Y, Okazumi S, et al. Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery. 2002;132:41–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A. 1997;94:1914–8.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Xu YW, Peng YH, Chen B, et al. Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma. Am J Gastroenterol. 2014;109:36–45.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Mashino K, Sadanaga N, Tanaka F, et al. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer. 2001;85:713–20.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Shan Q, Lou X, Xiao T, et al. A cancer/testis antigen microarray to screen autoantibody biomarkers of non-small cell lung cancer. Cancer Lett. 2013;328:160–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Healey GF, Lam S, Boyle P, et al. Signal stratification of autoantibody levels in serum samples and its application to the early detection of lung cancer. J Thorac Dis. 2013;5:618–25.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Yang Z, Chevolot Y, Géhin T, et al. Improvement of protein immobilization for the elaboration of tumor-associated antigen microarrays: application to the sensitive and specific detection of tumor markers from breast cancer sera. Biosens Bioelectron. 2013;40:385–92.PubMedCrossRefGoogle Scholar
  14. 14.
    Nakamura S, Nouso K, Noguchi Y, et al. Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma. J Gastroenterol Hepatol. 2006;21:1281–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Middleton CH, Irving W, Robertson JF, et al. Serum autoantibody measurement for the detection of hepatocellular carcinoma. PLoS ONE. 2014;9:e103867.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Fujiwara S, Wada H, Kawada J, et al. NY-ESO-1 antibody as a novel tumour marker of gastric cancer. Br J Cancer. 2013;108:1119–25.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Gati A, Lajmi N, Derouiche A, et al. NY-ESO-1 expression and immunogenicity in prostate cancer patients. Tunis Med. 2011;89:779–83.PubMedGoogle Scholar
  18. 18.
    Long YY, Wang Y, Huang QR, et al. Measurement of serum antibodies against NY-ESO-1 by ELISA: a guide for the treatment of specific immunotherapy for patients with advanced colorectal cancer. Exp Ther Med. 2014;8:1279–84.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Kagohashi K, Satoh H, Ishikawa H, et al. A re-evaluation of squamous cell carcinoma antigen (SCC) as a serum marker for non-small cell lung cancer. Med Oncol. 2008;25:187–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Shimada H, Ochiai T, Nomura F. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer. 2003;97:682–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Wada H, Isobe M, Kakimi K, et al. Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. J Immunother. 2014;37:84–92.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2015

Authors and Affiliations

  • Yoko Oshima
    • 1
  • Hideaki Shimada
    • 1
    Email author
  • Satoshi Yajima
    • 1
  • Tatsuki Nanami
    • 1
  • Kazuyuki Matsushita
    • 2
  • Fumio Nomura
    • 2
  • Osamu Kainuma
    • 3
  • Nobuhiro Takiguchi
    • 3
  • Hiroaki Soda
    • 3
  • Takeshi Ueda
    • 4
  • Toshihiko Iizasa
    • 5
  • Naoto Yamamoto
    • 6
  • Hiroshi Yamamoto
    • 3
  • Matsuo Nagata
    • 3
  • Sana Yokoi
    • 7
  • Masatoshi Tagawa
    • 8
  • Seiko Ohtsuka
    • 1
  • Akiko Kuwajima
    • 9
  • Akihiro Murakami
    • 9
  • Hironori Kaneko
    • 1
  1. 1.Department of Surgery, School of MedicineToho UniversityTokyoJapan
  2. 2.Molecular Diagnosis, Graduate School of MedicineChiba UniversityChibaJapan
  3. 3.Division of Gastroenterological SurgeryChiba Cancer CenterChibaJapan
  4. 4.Division of UrologyChiba Cancer CenterChibaJapan
  5. 5.Division of Thoracic DiseaseChiba Cancer CenterChibaJapan
  6. 6.Division of Breast SurgeryChiba Cancer CenterChibaJapan
  7. 7.Division of Clinical GenomicsChiba Cancer CenterChibaJapan
  8. 8.Division of Pathology and Cell TherapyChiba Cancer CenterChibaJapan
  9. 9.Medical & Biological Laboratories Co., LtdNagoyaJapan

Personalised recommendations